The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure

Haematologica

Volumn 91, Issue 11, 2006, Pages 1555-1558

  Raab, Marc S ^a,d   Breitkreutz, Iris ^a   Hundemer, Michael ^a   Benner, Axel ^c   Klaus, Jens ^a   Hegenbart, Ute ^a   Moehler, Thomas ^a   Ho, Anthony D ^a   Zeier, Martin ^a   Goldschmidt, Hartmut ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b National Center of Tumor Diseases   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dialysis; Multiple myeloma; Renal failure; Stem cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MALE; MORTALITY; MULTIPLE MYELOMA; SURVIVAL;

ADULT; AGED; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33750933844     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma- a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994;53:207-12.
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65:175-81.
3. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
5. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996;2:947-52.
6. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28-36.
7. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-60.
8. Rondeau V, Commenges D, Joly P. Maximum penalized likelihood estimation in a gamma-frailty model. Lifetime Data Analysis 2003;9:139-53.
9. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991;324:1845-51.
10. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
11. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823-8.
12. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005;75:27-3.
13. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
14. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-9.
15. Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, et al. Management of multiple myeloma and related-disorders: guidelines fom the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89:717-41.